Doctor Federico Felizzi

Novartis, Basel (Switzerland)

Follow

Contributor content

$Indirect treatment comparison of ARNI vs SGLT2i in heart failure with reduced ejection fraction: a reconciliation of previous network meta-analyses$

Presentation

Indirect treatment comparison of ARNI vs SGLT2i in heart failure with reduced ejection fraction: a reconciliation of previous network meta-analyses

ESC 365 is supported by

novartis

Explore sponsored resources